GLENMARKNSEGlenmark Pharmaceuticals Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 30 Jan, 2026 · 20:07 IST

Glenmark Q3 FY26 results: consolidated 9M revenue up 31%, standalone posts 9M loss

Revenue Growth 20pctExceptional ItemPat NegativeResults View source PDFExplain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-5.1%Reaction day
₹2026.10
prior close
₹1935.10
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-1.1%-4.0% vs market
Pharmaceuticals peers, median of 155sector-0.5%-4.6% vs sector

On the reaction day the stock moved 4.0 pts less than Nifty Midcap 150 and 4.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.6
10m
-1.1
15m
-0.3
30m
-1.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-5.1-1.1-4.0-0.5-4.6
Next day
-3.4+1.8-5.1+1.4-4.8
2d
-3.6+2.4-5.9+1.6-5.2
3d
-2.8+2.1-4.8+0.9-3.7
4d
-4.9+2.0-6.9+0.4-5.3
5d
-2.4+3.6-6.0+2.4-4.8
1w
-0.5+4.1-4.6+2.5-3.0
15d
+0.3+1.8-1.5+0.5-0.2
1m
+5.3-0.1+5.4-1.9+7.2
2m
+2.9-7.8+10.7-6.5+9.3
3m
+17.9+3.1+14.8+3.1+14.8
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q3 revenue rose 15% YoY to about Rs 39,006 million; 9M revenue up 31% to about Rs 1,32,119 million. Q3 consolidated profit after tax grew 16% to Rs 4,032 million. Standalone swung to a 9M loss of Rs 1,269 million (vs Rs 14,626 million profit last year) due to exceptional items of about Rs 16,108 million, including US antitrust settlements, inventory write-downs post GST 2.0, and Labour Code provisions. Auditors gave an unmodified review.

Likely market impact

Mixed: solid consolidated growth offset by standalone loss from one-off legal and restructuring charges; exceptional items largely behind it, watch margins